Micafungin for candidiasis

Mycoses

Volumn 55, Issue SUPPL.1, 2012, Pages 8-12

  Pappas, Peter G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Candidemia; Invasive candidiasis; Micafungin

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN;

ARTICLE; CANDIDA ALBICANS; CANDIDA ENDOCARDITIS; CANDIDA GLABRATA; CANDIDA OSTEOMYELITIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; DRUG DOSE ESCALATION; DRUG MEGADOSE; ESOPHAGUS CANDIDIASIS; FOLLOW UP; HUMAN; INVASIVE CANDIDIASIS; MUCOCUTANEOUS CANDIDIASIS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CANDIDA;

EID: 84859404851     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02112.x     Document Type: Article

References (20)

1. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-4.
2. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
3. Fridkin SK. Candidemia is costly-plain and simple. Clin Infect Dis 2005; 41: 1240-1.
4. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the US: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
5. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
6. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
7. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654-61.
8. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007; 369: 1519-27.
9. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
10. Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20: 475-81.
11. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of oesophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-9.
12. de Wet N, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of esophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899-907.
13. Morrison VA. Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 2006; 4: 325-42.
14. Dupont B, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009; 13: R159.
15. Horn DL, Ostrosky-Zeichner L, Morris MI, et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective micafungin trials. Eur J Clin Microbiol Infect Dis 2010; 29: 223-9.
16. Baddley JW, Benjamin DK, Patel M, et al. Candida infective endocarditis. Eur J Microbiol Infect Dis 2008; 27: 519-29.
17. Chopra T, Bhargava A, Kumar S, et al. Candida kefyr endocarditis in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci 2010; 339: 188-9.
18. Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135-40.
19. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized, double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-9.
20. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-5.